LÉVOSIMENDAN

C01CX08(WHO) In general: ℞ (Prescription only) 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile 141505-33-1Y 3033825 DB00922Y 2298414Y C6T4514L4E D04720Y CHEBI:50567Y ChEMBL313136N DTXSID9046445 Interactive image O=C2N/N=C(/c1ccc(N/N=C(\C#N)C#N)cc1)[C@H](C)C2 InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1YKey:WHXMKTBCFHIYNQ-SECBINFHSA-NY Levosimendan(INN) is acalciumsensitizer used in the management ofacutely decompensated congestive heart failure.‍‍‍‍‍‍​​​‍​​​​​​ It is marketed under thetrade nameSimdax(Orion Corporation). Overall the drug has a two fold mechanism of action. It leads to greaterinotropyby increasing the calcium sensitivity as it binds totroponinand this results in a greater positive inotrophic force. Secondly, the drug is able to openATP-sensitive potassium channels invascular smooth musclecells, and the vascular dilatory effects of the drug lead to a decreasedpreloadandafterload, putting less work on the heart. This drug is in the process of review by theFDAbut has not been approved for use in the United States yet.